Phase III Trial Initiated for Cadonilimab in Perioperative Colon Cancer

AI-generated NewsSnap summary based on source reporting.
Published: 2026-10-10
Category: health
Source: The Clinical Trial Vanguard

A Phase III clinical trial has begun, enrolling its first patient on October 10, 2026, to evaluate cadonilimab as a monotherapy for the neoadjuvant and adjuvant treatment of resectable MSI-H/dMMR colon cancer. The trial aims to achieve durable cure by targeting the perioperative window.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai